<DOC>
	<DOC>NCT00615446</DOC>
	<brief_summary>This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors</brief_summary>
	<brief_title>A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists Patient has good performance status (ECOG 0 or 1) Prior treatment with either gemcitabine or SU011248 Hypertension that cannot be controlled by medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>solid tumor malignancy, SU011248, sunitinib, neoplasms</keyword>
</DOC>